12:19 PM EDT, 09/16/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)

Nuvalent ( NUVL ) shares jumped 22% in recent Monday trading after the company said data from clinical studies of zidesamtinib and NVL-655 to treat patients with non-small cell lung cancer showed "favorable tolerability."

The company said Saturday the parallel phase 1/2 trials established preliminary clinical proof-of-concept for zidesamtinib and NVL-655 as "TRK-sparing TKIs that have the potential to move up the treatment paradigm."

Nuvalent ( NUVL ) expects pivotal data from both programs in 2025.

Price: 106.46, Change: +19.01, Percent Change: +21.27